Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 5th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 5th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 3rd 2015

Antihypertensive Drug Could Be an Inexpensive Anticancer Agent

Surabhi Dangi-Garimella, PhD

A new research study published in the Journal of Dermatology has found that propranolol, a commonly used antihypertensive agent, could substantially reduce proliferation of angiosarcoma.

November 3rd 2015

ASCO Confirms Support for the President's Nominee for FDA Commissioner

AJMC Staff

Fifty organizations, including the American Society of Clinical Oncology, have expressed their confidence in Robert Califf, MD, to lead the FDA.

November 3rd 2015

Impact of ASCO Results Hold: Pembrolizumab Granted Breakthrough in Advanced CRC

Surabhi Dangi-Garimella, PhD

After melanoma and non-small cell lung cancer, the FDA has granted Breakthrough Therapy status to pembrolizumab in advanced colorectal cancer patients with mismatched repair deficiency.

October 31st 2015

This Week in Managed Care: October 31, 2015

This week in managed care, The American Journal of Managed Care celebrated 20 years and presented its first Emerging Leader award, plus confusion reigns after study links processed meats to cancer and death rates on the decline.

October 30th 2015

UnitedHealthcare to Expand Existing Bundled Payment Model in Oncology

Surabhi Dangi-Garimella, PhD

With the expansion, UnitedHealthcare will bring 5 more oncology practices on board to participate in its bundled program, which will grow the program to 650 oncologists across 7 states.

October 30th 2015

Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents

Although there have been a number of new value calculators created recently, UnitedHealthcare does not plan to use any just now. Instead, it will continue covering regimens recommended by the National Comprehensive Cancer Network and in a few years the company will use data from its prior authorization tool to analyze performance of regimens, explained Lee Newcomer, MD, MHA, senior vice president, Oncology, Genetics and Women's Health, UnitedHealthcare.

October 30th 2015

Ted Okon Outlines the Purpose of COA's Payer Exchange Summit

The Community Oncology Alliance (COA) created its Payer Exchange Summit to get payers who are thinking about getting involved in oncology payment reform or want to know what to do exposed to successful pilots, explained Ted Okon, MBA, executive director of COA.

October 30th 2015

Dr Julie M. Vose to Discuss Value, Quality, and Cost in AJMC Tweetchat

On November 3, at 11 a.m. EST, the president of the American Society of Clinical Oncology will host a tweetchat with The American Journal of Managed Care. Get a preview of Dr. Julie Vose's speech at Patient-Centered Oncology Care.

October 29th 2015

Challenges With Transforming Into an Oncology Medical Home

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit on Oncology Payment Reform, hosted by the Community Oncology Alliance, Daniel McKellar, MD, who chairs the Commission on Cancer, insisted on meaningful feedback from the community to ensure adequate transformation of practices into a medical home.

October 29th 2015

Medicaid Coverage for Smoking Cessation Improves, but Barriers Remain, CDC Finds

Mary K. Caffrey

More states cover all recommended evidence-based treatments, although many require copayments or put annual limits on care.

October 29th 2015

How Could Genetic Testing Have the Most Impact?

October 29th 2015

Role of Genetic versus Genomic Testing in Cancer

October 29th 2015

Can Genomic Testing Help Offset Cancer Care Costs?

October 29th 2015

Role of Genetic vs Genomic Testing in Cancer

October 29th 2015

Challenges With Personalized Medicine

October 29th 2015

Thoughts on New Developments in Clinical Cancer Care Management

October 29th 2015

Impact of Personalized Medicine on Specific Tumor Types

October 29th 2015

Impact of Personalized Medicine on Treatment Decisions

October 29th 2015

The Value of Personalized Medicine

October 29th 2015

Evolution of Personalized Medicine and Positive Outcomes

October 29th 2015

Applying Personalized Medicine to Impact Outcomes in Different Cancer Types

October 29th 2015

Coverage Decisions for Personalized Medicine

October 29th 2015

Advantages of a Personalized Approach to Cancer Care

October 29th 2015

Evolution of Personalized Medicine

October 29th 2015

Olaparib Effective in mCRPC

Surabhi Dangi-Garimella, PhD

Olaparib, a PARP inhibitor approved for treating BRCA1/2-mutated ovarian cancer, has been found effective in treating men with metastatic, castrate-resistant prostate cancer.

October 29th 2015

Ipilimumab Approved in Adjuvant Setting to Prevent Relapse in Advanced Melanoma

Surabhi Dangi-Garimella, PhD

The drug significantly delayed recurrence of the cancer in patients treated post surgery.

October 28th 2015

Payment Reform Pilot Updates at the COA Payer Summit

Surabhi Dangi-Garimella, PhD

Payer—provider teams presented updates on their cost-saving pilot projects and looked to the future of these models in oncology care.

October 28th 2015

Cost Questions Will Follow the Approval of Amgen's Oncolytic Viral Treatment, Imlygic

Surabhi Dangi-Garimella, PhD

The company says the treatment will cost an average of $65,000.

October 27th 2015

ASCO Demands Revamp of Site Neutrality Policy in Oncology

Surabhi Dangi-Garimella, PhD

The ASCO statement emphasizes patient-centered reform that weighs-in the value of the services rendered.

October 27th 2015

Confusion Reigns in Wake of Study Linking Processed Meat to Cancer

Mary K. Caffrey

A study shows too much conflicting dietary advice causes some people to tune it all out. Nuances in the report from WHO are lost on most consumers.

...

118 119 120 121 122 123 124 125 126

...

186 >